Publications by authors named "Jesus García-Donas"

55Publications

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:
Aline Talhouk Joshy George Chen Wang Timothy Budden Tuan Zea Tan Derek S Chiu Stefan Kommoss Huei San Leong Stephanie Chen Maria P Intermaggio Blake Gilks Tayyebeh M Nazeran Mila Volchek Wafaa Elatre Rex C Bentley Janine Senz Amy Lum Veronica Chow Hanwei Sudderuddin Robertson Mackenzie Samuel C Y Leong Geyi Liu Dustin Johnson Billy Chen Aocs Group Jennifer Alsop Susana N Banerjee Sabine Behrens Clara Bodelon Alison H Brand Louise Brinton Michael E Carney Yoke-Eng Chiew Kara L Cushing-Haugen Cezary Cybulski Darren Ennis Sian Fereday Renée T Fortner Jesús García-Donas Aleksandra Gentry-Maharaj Rosalind Glasspool Teodora Goranova Casey S Greene Paul Haluska Holly R Harris Joy Hendley Brenda Y Hernandez Esther Herpel Mercedes Jimenez-Linan Chloe Karpinskyj Scott H Kaufmann Gary L Keeney Catherine J Kennedy Martin Köbel Jennifer M Koziak Melissa C Larson Jenny Lester Liz-Anne Lewsley Jolanta Lissowska Jan Lubiński Hugh Luk Geoff Macintyre Sven Mahner Iain A McNeish Janusz Menkiszak Nikilyn Nevins Ana Osorio Oleg Oszurek José Palacios Samantha Hinsley Celeste L Pearce Malcolm C Pike Anna M Piskorz Isabelle Ray-Coquard Valerie Rhenius Cristina Rodriguez-Antona Raghwa Sharma Mark E Sherman Dilrini De Silva Naveena Singh Peter Sinn Dennis Slamon Honglin Song Helen Steed Euan A Stronach Pamela J Thompson Aleksandra Tołoczko Britton Trabert Nadia Traficante Chiu-Chen Tseng Martin Widschwendter Lynne R Wilkens Stacey J Winham Boris Winterhoff Alicia Beeghly-Fadiel Javier Benitez Andrew Berchuck James D Brenton Robert Brown Jenny Chang-Claude Georgia Chenevix-Trench Anna deFazio Peter A Fasching María J García Simon A Gayther Marc T Goodman Jacek Gronwald Michelle J Henderson Beth Y Karlan Linda E Kelemen Usha Menon Sandra Orsulic Paul D P Pharoah Nicolas Wentzensen Anna H Wu Joellen M Schildkraut Mary Anne Rossing Gottfried E Konecny David G Huntsman Ruby Yun-Ju Huang Ellen L Goode Susan J Ramus Jennifer A Doherty David D Bowtell Michael S Anglesio

Clin Cancer Res 2020 Oct 17;26(20):5411-5423. Epub 2020 Jun 17.

British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572656PMC
October 2020

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.

Target Oncol 2020 06;15(3):391-406

Medical Oncology Department, Centre François Baclesse, Université Unicaen and GINECO, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-020-00715-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283207PMC
June 2020

MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer.

Urol Oncol 2020 07 18;38(7):640.e23-640.e29. Epub 2020 Feb 18.

Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.01.012DOI Listing
July 2020

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

N Engl J Med 2019 12 28;381(25):2403-2415. Epub 2019 Sep 28.

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C.); University of Chicago Medicine (G.F.F.) and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University (D.C.), Chicago, and AbbVie, North Chicago (D.M.S., B.A.B., S.B., C.K.R., P.J.A., M.H.D.) - all in Illinois; NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo (M.F.B.), and Memorial Sloan Kettering Cancer Center, New York (K.B.-M., C.A.) - both in New York; University of Washington-Seattle Cancer Care Alliance, Seattle (E.M.S.); Lillebaelt University Hospital of Southern Denmark, Vejle, and the University of Southern Denmark, Odense (K.D.S.); Prince of Wales Clinical School, University of New South Wales and Royal Hospital for Women (M.F.), and the Northern Cancer Institute (S.B.-H.), Sydney; Jikei University School of Medicine, Tokyo (A. Okamoto), and Aichi Cancer Center Hospital, Nagoya (M.M.) - both in Japan; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (T.L.W.); Texas Oncology, U.S. Oncology Research Network, Fort Worth (N.G.C.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin); Women and Infants Hospital, Providence, RI (P.A.D.); Penn Medicine, Philadelphia (M.A.M.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.-H.N.); O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham (C.A.L.); Oxford University Hospitals, Oxford, United Kingdom (S.N.); Washington University School of Medicine, St. Louis (A.R.H.); Kaiser Permanente Northern California, San Francisco (R.D.L., M.A.B.); and H.M. Hospitales-Centro Integral Oncológico H.M. Clara Campal, Madrid (J.G.-D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1909707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941439PMC
December 2019

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

N Engl J Med 2019 07;381(4):338-348

From Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Université Paris-Saclay, Villejuif, France (Y.L.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Genitourinary and Gynecological Cancer Unit, Centro Integral Oncológico Clara Campal, Madrid (J.G.-D.), Hospital Clinic Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (B.M.), and Hospital Universitario Marques de Valdecilla, Santander (I.D.) - all in Spain; the Institute of Cancer Research, Sutton, London (R.H.); the Levine Cancer Institute, Atrium Health, Charlotte, NC (E.B.); Virginia Oncology Associates, US Oncology Research, Norfolk (M.F.); Norton Healthcare, Louisville, KY (A.R.); the Altai Regional Cancer Center, Barnaul, Russia (S.V.); the Penn State Cancer Institute, Hershey (M.J.), and Janssen Research and Development, Spring House (B.Z., A.S.-W., A.O., A.A.) - both in Pennsylvania; Weill Cornell Medical College, New York (S.T.T.); University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City (Y.Z.); Janssen Research and Development, Beerse, Belgium (K.S., P.D.P.); and the University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1817323DOI Listing
July 2019

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Authors:
Peter F Rambau Robert A Vierkant Maria P Intermaggio Linda E Kelemen Marc T Goodman Esther Herpel Paul D Pharoah Stefan Kommoss Mercedes Jimenez-Linan Beth Y Karlan Aleksandra Gentry-Maharaj Usha Menon Susanna Hernando Polo Francisco J Candido Dos Reis Jennifer Anne Doherty Simon A Gayther Raghwa Sharma Melissa C Larson Paul R Harnett Emma Hatfield Jurandyr M de Andrade Gregg S Nelson Helen Steed Joellen M Schildkraut Micheal E Carney Estrid Høgdall Alice S Whittemore Martin Widschwendter Catherine J Kennedy Frances Wang Qin Wang Chen Wang Sebastian M Armasu Frances Daley Penny Coulson Micheal E Jones Micheal S Anglesio Christine Chow Anna de Fazio Montserrat García-Closas Sara Y Brucker Cezary Cybulski Holly R Harris Andreas D Hartkopf Tomasz Huzarski Allan Jensen Jan Lubiński Oleg Oszurek Javier Benitez Fady Mina Annette Staebler Florin Andrei Taran Jana Pasternak Aline Talhouk Mary Anne Rossing Joy Hendley Robert P Edwards Sian Fereday Francesmary Modugno Roberta B Ness Weiva Sieh Mona A El-Bahrawy Stacey J Winham Jenny Lester Susanne K Kjaer Jacek Gronwald Peter Sinn Peter A Fasching Jenny Chang-Claude Kirsten B Moysich David D Bowtell Brenda Y Hernandez Hugh Luk Sabine Behrens Mitul Shah Audrey Jung Prafull Ghatage Jennifer Alsop Kathryn Alsop Jesús García-Donas Pamela J Thompson Anthony J Swerdlow Chloe Karpinskyj Alicia Cazorla-Jiménez María J García Susha Deen Lynne R Wilkens José Palacios Andrew Berchuck Jennifer M Koziak James D Brenton Linda S Cook Ellen L Goode David G Huntsman Susan J Ramus Martin Köbel

J Pathol Clin Res 2018 10 21;4(4):250-261. Epub 2018 Sep 21.

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cjp2.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174617PMC
October 2018

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Authors:
Ellen L Goode Matthew S Block Kimberly R Kalli Robert A Vierkant Wenqian Chen Zachary C Fogarty Aleksandra Gentry-Maharaj Aleksandra Tołoczko Alexander Hein Aliecia L Bouligny Allan Jensen Ana Osorio Andreas Hartkopf Andy Ryan Anita Chudecka-Głaz Anthony M Magliocco Arndt Hartmann Audrey Y Jung Bo Gao Brenda Y Hernandez Brooke L Fridley Bryan M McCauley Catherine J Kennedy Chen Wang Chloe Karpinskyj Christiani B de Sousa Daniel G Tiezzi David L Wachter Esther Herpel Florin Andrei Taran Francesmary Modugno Gregg Nelson Jan Lubiński Janusz Menkiszak Jennifer Alsop Jenny Lester Jesús García-Donas Jill Nation Jillian Hung José Palacios Joseph H Rothstein Joseph L Kelley Jurandyr M de Andrade Luis Robles-Díaz Maria P Intermaggio Martin Widschwendter Matthias W Beckmann Matthias Ruebner Mercedes Jimenez-Linan Naveena Singh Oleg Oszurek Paul R Harnett Peter F Rambau Peter Sinn Philipp Wagner Prafull Ghatage Raghwa Sharma Robert P Edwards Roberta B Ness Sandra Orsulic Sara Y Brucker Sharon E Johnatty Teri A Longacre Eilber Ursula Valerie McGuire Weiva Sieh Yanina Natanzon Zheng Li Alice S Whittemore deFazio Anna Annette Staebler Beth Y Karlan Blake Gilks David D Bowtell Estrid Høgdall Francisco J Candido dos Reis Helen Steed Ian G Campbell Jacek Gronwald Javier Benítez Jennifer M Koziak Jenny Chang-Claude Kirsten B Moysich Linda E Kelemen Linda S Cook Marc T Goodman María José García Peter A Fasching Stefan Kommoss Suha Deen Susanne K Kjaer Usha Menon James D Brenton Paul DP Pharoah Georgia Chenevix-Trench David G Huntsman Stacey J Winham Martin Köbel Susan J Ramus

JAMA Oncol 2017 12;3(12):e173290

School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.3290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744673PMC
December 2017

mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter.

Clin Cancer Res 2017 09;23(17):5320

Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1280DOI Listing
September 2017

Genotyping the Host in the Battle Against Cancer.

Eur Urol Focus 2016 Dec 16;2(6):640-641. Epub 2016 May 16.

Genitourinary and Gynecological Cancer Unit, HM Hospitales - Centro Integral Oncológico HM Clara Campa, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.05.002DOI Listing
December 2016

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.

Pharmacogenet Genomics 2017 06;27(6):227-231

aHereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO) bOncology Department, Hospital Universitario 12 de Octubre cSpanish Oncology Genitourinary Group (SOGUG) dISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain eDepartment of Clinical Pharmacy and Toxicology fDepartment of Medical Oncology gDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden hDepartment of Medical Oncology, VU University Medical Center, Amsterdam iDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands jDepartment of Solid Tumour Oncology, Cleveland Clinic Foundation (CCF) Taussig Cancer Institute, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000280DOI Listing
June 2017

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Eur Urol 2015 Oct 27;68(4):621-9. Epub 2015 Apr 27.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands; Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.04.018DOI Listing
October 2015

Surgical outcomes and complications of prophylactic salpingectomy at the time of benign hysterectomy in premenopausal women.

J Minim Invasive Gynecol 2015 May-Jun;22(4):653-7. Epub 2015 Feb 24.

Gynecology Oncology Unit, Medical Oncology Department. HM Hospitales, Centro Integral Oncológico Clara Campal, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmig.2015.02.013DOI Listing
October 2015

Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

World J Clin Oncol 2014 May;5(2):86-92

Lucas Minig, María Guadalupe Patrono, Gynecologic Oncology Program, Clara Campal Comprehensive Cancer Center, HM Hospitales, 28050 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v5.i2.86DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014800PMC
May 2014

Circulating and disseminated tumor cells in ovarian cancer: a systematic review.

Gynecol Oncol 2014 Jun 19;133(3):632-9. Epub 2014 Mar 19.

Division of Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.03.016DOI Listing
June 2014

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.

Urol Oncol 2015 Apr 1;33(4):179-86. Epub 2014 Feb 1.

Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2013.09.015DOI Listing
April 2015

Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment.

Ecancermedicalscience 2013 Dec 17;7:379. Epub 2013 Dec 17.

Gynaecology Oncology Programme, Medical Oncology, Comprehensive Oncology Centre Clara Campal, HM Hospitals, Madrid 28050, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2013.379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869475PMC
December 2013

Molecular markers to predict response to therapy.

Semin Oncol 2013 Aug;40(4):444-58

Genitourinary Tumors Programme Centro Integral Oncologico Clara Campal CIOCC, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.05.005DOI Listing
August 2013

Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.

Crit Rev Oncol Hematol 2013 Oct 4;88(1):154-67. Epub 2013 Apr 4.

Division of Medical Oncology, Centro Integral Oncologico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain; Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.03.002DOI Listing
October 2013

Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.

Pharmacogenomics 2012 Nov;13(14):1621-33

Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, CNIO, Melchor Fernández Almagro 3, 28029 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.142DOI Listing
November 2012

Current management of uterine sarcomas.

Clin Transl Oncol 2011 May;13(5):307-14

Medical Oncology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-011-0659-0DOI Listing
May 2011

Knowledge of hereditary renal cancer syndromes: a pending issue for oncologists.

Anticancer Drugs 2011 Jan;22 Suppl 1:S15-20

Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000390768.93282.65DOI Listing
January 2011

Retrorectal cystic hamartoma as benign cause of CA 19-9 elevation.

J Clin Oncol 2007 Sep;25(25):4012-4

Department of Medical Oncology, Fundación Hospital Alcorcón, Alcorcón, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.12.4214DOI Listing
September 2007